Invasive fungal infections (IFIs) account for an estimated 6.5 million cases and 3.8 million deaths annually. In 2022, the World Health Organisation identified Cryptococcus neoformans, Candidozyma auris, and Candida albicans as pathogens of critical concern. Cryptococcal meningitis has a mortality rate of 76%, while Candida bloodstream infections and invasive candidiasis result in nearly one million deaths each year. These figures underscore the urgent need for effective antifungal therapies. Current treatments are limited, with three of the four major drug classes targeting the fungal cell membrane. Owing to the high genomic similarity between human and fungal cells, these treatments are often toxic. The emergence of multidrug-resistant (MDR) fungal strains further restricts the use of existing antifungals.
Cationic cyclic peptides (CCPs) offer a promising alternative. These positively charged peptides interact with negatively charged phospholipids in the fungal cell membrane, enabling penetration of a lipophilic moiety that induces fungicidal activity. ROB072, a novel CCP developed by the Robertson Group, has demonstrated potent efficacy against pathogenic yeasts, including C. neoformans, C. auris, and C. albicans. Ongoing research focuses on optimising ROB072 through structure-activity relationship studies, and its potential to combat MDR fungal pathogens represents a critical advancement in the treatment of IFIs.